Evidence reference only. Not medical advice, not a dosing guide, and not a recommendation to use any drug.
Echo The Echo Compendium
<- All drugs

Ecnoglutide

MARKETED

Long-acting cAMP-biased GLP-1 receptor agonist

5
graded results
0
ongoing records
4
effect domains
Evidence spread
High evidence 0Moderate evidence 4Low evidence 0Very low evidence 1

Ecnoglutide has a current marketed status in the scoped regulatory record below. Results describe observations and do not provide treatment advice.

Dated status sources

MARKETED China; Chronic weight management; Subcutaneous injection; as of 2026-07-13. Sciwind Biosciences reporting NMPA approval

The grade rates how strong the evidence is, not how good or safe the drug is. A low or very-low grade means the evidence is thin, not that an effect is harmful or ruled out.

Thin or bounded evidence here means uncertainty remains visible. It is not evidence that an effect has been ruled out.
Ecnoglutide MARKETED
pharmacology Decrease
Moderate evidence

CLARIFICATION RECORD: ecnoglutide (XW003, Sciwind Biosciences) is NOT an oral small-molecule GLP-1RA. It is an injectable long-acting modified GLP-1(7-37) PEPTIDE...

Zhang et al., Nat Commun 2024;15:8408 (phase 2 T2D); Lancet Diabetes Endocrinol 2025 (pha... Source
Full findingCLARIFICATION RECORD: ecnoglutide (XW003, Sciwind Biosciences) is NOT an oral small-molecule GLP-1RA. It is an injectable long-acting modified GLP-1(7-37) PEPTIDE (Ala8->Val8 plus C18 fatty-acid conjugation at Lys30), once-weekly s.c., and a cAMP signalling-BIASED GLP-1R agonist. Phase 2 (T2D, N=145, China, 20 wk): HbA1c -1.81/-1.90/-2.39% (0.4/0.8/1.2 mg) vs -0.55% placebo; 33.3% of 1.2 mg achieved >=5% weight loss vs 3.0% placebo. Phase 3 obesity and T2D (EECOH/EECOH-1) reported.
PopulationPhase 2 T2D: 145 adults, China, once-weekly s.c., 20 wk, placebo-controlled; phase 3 obesity and T2D (EECOH/EECOH-1)
Fundingindustry - Hangzhou Sciwind Biosciences (sponsor of record; disclosed)
Comparatorsplacebo
Ecnoglutide MARKETED
pharmacology Not directional
Very low evidence

cAMP-biased GLP-1 analog (Ala8Val + C18 diacid fatty-acid acylation): potent cAMP induction with minimal receptor internalisation; long half-life supporting...

Guo W et al. Discovery of ecnoglutide - a novel, long-acting, cAMP-biased GLP-1 analog. M... Source
Full findingcAMP-biased GLP-1 analog (Ala8Val + C18 diacid fatty-acid acylation): potent cAMP induction with minimal receptor internalisation; long half-life supporting once-weekly dosing.
PopulationIn vitro, db/db mice, DIO rats, phase 1 humans (NCT04389775)
Fundingacademic/independent analysis (manufacturer not study sponsor; per-study COI not individually audited)
Comparatorssemaglutide (preclinical)
Thin or bounded evidence here means uncertainty remains visible. It is not evidence that an effect has been ruled out.
Ecnoglutide MARKETED
glycaemic Decrease
Moderate evidence

The cAMP-biased GLP-1 agonist ecnoglutide lowered HbA1c by up to ~2.4% in phase-2 type-2 diabetes.

Ecnoglutide in type 2 diabetes, phase-2, Nat Commun 2024 Source
PopulationPeer-reviewed RCT / meta-analysis
FundingSciwind Biosciences
Thin or bounded evidence here means uncertainty remains visible. It is not evidence that an effect has been ruled out.
Ecnoglutide MARKETED
Stomach and gut Increase
Moderate evidence

Most adverse events mild-to-moderate GI; few discontinuations.

Ji L et al. Efficacy and safety of a biased GLP-1 receptor agonist ecnoglutide in adults ... Source
PopulationPhase 3 N=664 (NCT05813795); 40 wk; placebo comparator
Fundingindustry - Hangzhou Sciwind Biosciences (trial sponsor, disclosed in publication)
Comparatorsplacebo
Thin or bounded evidence here means uncertainty remains visible. It is not evidence that an effect has been ruled out.
Ecnoglutide MARKETED
weight-loss Decrease
Moderate evidence

Phase 3 (China): superior, sustained weight reduction vs placebo at 40 weeks in overweight/obese adults without diabetes.

Ji L et al. Efficacy and safety of a biased GLP-1 receptor agonist ecnoglutide in adults ... Source
PopulationPhase 3 RCT (NCT05813795), N=664, 36 Chinese centres, overweight/obese without diabetes; 40 wk; once-weekly SC; placebo comparator
Fundingindustry - Hangzhou Sciwind Biosciences (trial sponsor, disclosed in publication)
Comparatorsplacebo